Related Experiment Video
Updated: Aug 10, 2026
03:57
Electrochemotherapy of Tumours
Published on: December 15, 2008
Evolution of chemotherapy with platinum compounds
1Department of Pathology, Marshall University School of Medicine, Huntington, WV 25704, USA.
Annals of Clinical and Laboratory Science
|October 21, 1999
Summary
Cisplatin revolutionized cancer treatment, but side effects and resistance limit its use. Strategies like hydration, drug combinations, and analogues like carboplatin enhance efficacy and reduce toxicity, advancing platinum-based chemotherapy.
Area of Science:
- Oncology
- Pharmacology
Background:
- Cancer remains a significant global health burden and cause of mortality.
- Cisplatin, a platinum-based chemotherapy agent, transformed cancer treatment but faces challenges.
- Limitations include severe side effects and the development of cisplatin-resistant tumors.
Purpose of the Study:
- To review advancements in cisplatin chemotherapy.
- To explore strategies for overcoming cisplatin resistance and toxicity.
- To highlight the evolving role of platinum-based anti-cancer agents.
Main Methods:
- Review of clinical strategies to mitigate cisplatin toxicity.
- Analysis of combination chemotherapy regimens involving cisplatin.
- Examination of cisplatin analogues for improved therapeutic profiles.
Main Results:
- Protective measures (hydration, dosing schedules) enable higher cisplatin doses and combat resistance.
- Combination therapies enhance cisplatin effectiveness and allow dose reduction, minimizing toxicity.
- Cisplatin analogues, such as carboplatin, offer reduced toxicity and improved activity against resistant cancers.
Conclusions:
- Ongoing evolution of platinum-based chemotherapy aims to maximize therapeutic benefits.
- Strategies discussed expand the scope and promise of platinum anti-cancer agents.
- Further research continues to refine cisplatin and its analogues for broader clinical application.
More Related Videos
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...